Fractyl Health宣布,其针对GLP-1受体激动剂治疗后体重维持的Revita®疗法,已顺利完成REMAIN-1关键研究队列的随机化分组工作。这一里程碑标志着该创新代谢干预方案向临床验证迈出关键一步。
随机化过程的完成,为评估Revita®在维持减肥效果方面的有效性与安全性奠定了坚实基础。研究结果有望为接受GLP-1治疗后面临体重反弹难题的患者提供全新解决方案。
Fractyl Health宣布,其针对GLP-1受体激动剂治疗后体重维持的Revita®疗法,已顺利完成REMAIN-1关键研究队列的随机化分组工作。这一里程碑标志着该创新代谢干预方案向临床验证迈出关键一步。
随机化过程的完成,为评估Revita®在维持减肥效果方面的有效性与安全性奠定了坚实基础。研究结果有望为接受GLP-1治疗后面临体重反弹难题的患者提供全新解决方案。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.